WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018049127) 1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, AUTOIMMUNE AND CANCER DISEASES AND CONDITIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/049127    International Application No.:    PCT/US2017/050634
Publication Date: 15.03.2018 International Filing Date: 08.09.2017
IPC:
A61K 31/519 (2006.01), A61K 31/4162 (2006.01), C07D 339/04 (2006.01)
Applicants: SABILA BIOSCIENCES LLC [US/US]; 5 Overlook Road New City, NY 10956 (US)
Inventors: MANSOUR, Tarek, S.; (US).
EVANS, Collen, E.; (US)
Agent: BARNHARD, Elizabeth, M.; (US).
LEASON, David; (US).
ELLIS, Edward, J.; (US).
CHENG, Susie; (US).
BARNHARD, Elizabeth, M.; (US)
Priority Data:
62/384,813 08.09.2016 US
Title (EN) 1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, AUTOIMMUNE AND CANCER DISEASES AND CONDITIONS
(FR) COMPOSÉS 1,2-DITHIOLANE UTILES DANS LA NEUROPROTECTION, LES MALADIES ET LES ÉTATS AUTO-IMMUNS ET CANCÉREUX
Abstract: front page image
(EN)This invention provides confounds of the formula (I): wherein Y1, Y2 Z, X1, X2, and W are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and Ρ13K/ΑΚΤ/mTor signaling pathway kinases-mediated diseases; or conditions, such as neurodegeneration, neuroprotection, cancer, autoimmune as well as other diseases and conditions associated with the modulation of tyrosine kinases selected from FYN, FYN Y531F, FLT3, FLT3 -ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, and ROSI; MAPK pathway kinases selected from ARAF, BRAE CRAP, ERK1 /2, MEK1, MEK2, MEK3, MEK4, MEK5. MEK6, and MEK7; and P13K/AKT/mTor pathway kinases: selected from mTor, P13K a, Ρ13Κ β, P13Kγ, and P13K δ.
(FR)La présente invention concerne des composés de formule (I) : Y1, Y2 Z, X1, X2, et W étant définis dans la description. Ces composés sont utiles dans le traitement des maladies à médiation par les tyrosines kinases, les kinases à voie de signalisation MAPK et les kinases à voie de signalisation Ρ13K/ΑΚΤ/mTor ; ou les états, tels que les maladies et les états de neurodégénérescence, de neuroprotection, liés au cancer, auto-immuns ainsi que d’autres maladies et états associés à la modulation des tyrosines kinases sélectionnées parmi FYN, FYN Y531F, FLT3, FLT3-ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, et ROSI ; les kinases à voie MAPK sélectionnées parmi ARAF, BRAE CRAP, ERK1 /2, MEK1, MEK2, MEK3, MEK4, MEK5. MEK6, et MEK7 ; et les kinases à voie P13K/AKT/mTor : sélectionnées parmi mTor, P13K α, Ρ13Κ β, P13Kγ, et P13K δ.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)